9月8日，施贵宝盘中下跌3.05%，报64.575美元/股，成交额4231.81万美元。尽管公司当日宣布其潜在首创GPRC5D靶向CAR-T细胞疗法Arlocabtagene Autoleucel的注册性II期试验达到主要及关键次要终点，总缓解率与完全缓解率双双达标，但积极数据未能扭转跌势。
消息面上，CAR-T领域安全风波持续发酵。此前施贵宝已因观察到"短暂且可逆的炎症事件"而主动暂停Zola-Cel在自身免疫性疾病领域的临床试验入组，同行诺华亦因3例患者死亡暂停rap-cel多项研究。制药板块整体承压，诺华当日大跌12.52%，强生跌2.91%，默沙东跌2.09%，行业性利空情绪显著压制个股表现。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.